Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
Provided By GlobeNewswire
Last update: Mar 13, 2025
FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)
Assuming FDA approval, proposed launch in PSVT targeted for mid-2025
Read more at globenewswire.com
